USA TODAY's Rita Rubin reports that researchers are investigating whether the same approach used to prevent infectious diseases could treat addictions to such drugs as nicotine.
Nabi Pharmaceuticals has gotten a $10-million grant to study the effectiveness and to monitor the side effects of a smoking-cessation vaccine. Nabi, based in Rockville, Md., expects to begin enrolling patients in the NicVax study by year's end.
No comments:
Post a Comment